首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents.
【24h】

Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents.

机译:新型的羟基氨基脲的席夫碱的合成,生物学评估和定量构效关系分析作为潜在的抗肿瘤药物。

获取原文
获取原文并翻译 | 示例
           

摘要

Thirty Schiff bases of hydroxysemicarbazide (Ar-CH=NNHCONHOH) have been synthesized and tested against L1210 murine leukemia cells. The IC(50) values were found to be in a range from 2.7 x 10(-6) to 9.4 x 10(-4) M. A total of 17 out of the 30 compounds had higher inhibitory activities than hydroxyurea (an anticancer drug currently used for the treatment of melanoma, leukemia, and ovarian cancer) against L1210 cells. Six compounds with IC(50) values in micromolar range were 11- to 30-fold more potent than hydroxyurea (IC(50) = 8.2 x 10(-5) M). The partition coefficient (log P) and ionization constants (pK(a)) of a model compound [1-(3-trifluoromethylbenzylidene)-4-hydroxysemicarbazide, 1] were measured by the shake-flask method, and the measured log P was used to derive Hansch-Fujita pi constant of -CH=NNHCONHOH. On the basis of the newly derived pi and those of other moieties, the partition coefficients (SlogP) of the other 29 compounds were calculated by the summation of pi values. Quantitative structure-activity relationship (QSAR) analysis showed that, besides the essential pharmacophore (-NHCONHOH), hydrophobicity (SlogP), molecular size/polarizability (calculated molar refractivity), and the presence of an oxygen-containing group at the ortho position (I) were important determinants for the antitumor activities. In conclusion, the results obtained in this study show that several Schiff bases of hydroxysemicarbazide are potent inhibitors of tumor cells and warrant further investigation as cancer chemotherapeutic agents.
机译:已合成了30种羟基氨基脲的席夫碱(Ar-CH = NNHCONHOH),并针对L1210鼠白血病细胞进行了测试。发现IC(50)值在2.7 x 10(-6)至9.4 x 10(-4)M的范围内。30种化合物中的17种具有比羟基脲(一种抗癌药)更高的抑制活性。目前用于治疗针对L1210细胞的黑色素瘤,白血病和卵巢癌。 IC(50)值在微摩尔范围内的六种化合物的效力比羟基脲高11至30倍(IC(50)= 8.2 x 10(-5)M)。通过摇瓶法测定模型化合物[1-(3-三氟甲基亚苄基)-4-羟基氨基脲的模型的分配系数(log P)和电离常数(pK(a)),测得的log P为用于推导-CH = NNHCONHOH的Hansch-Fujita pi常数。根据新获得的pi和其他部分的pi,通过pi值的总和计算出其他29种化合物的分配系数(SlogP)。定量构效关系(QSAR)分析表明,除基本药效团(-NHCONHOH)外,疏水性(SlogP),分子大小/极化率(计算的摩尔折射率)和邻位有一个含氧基团( I)是抗肿瘤活性的重要决定因素。总之,本研究获得的结果表明,羟基氨基脲的几种席夫碱是有效的肿瘤细胞抑制剂,作为癌症化疗药物有待进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号